Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Luxturna (voretigene neparvovec) for the Treatment of Biallelic RPE65 Mutation-Associated Retinal Dystrophy

Drug (Brand/Generic)

Luxturna/voretigene neparvovec

Developed by

Spark Therapeutics

Therapy Class

Gene therapy

Current Indication

Biallelic RPE65 mutation-associated retinal dystrophy

Market Sector

Ophthalmology

Development Status

Approved in the US
Expand

Go Top